Potential Papain-like Protease Inhibitors Against COVID-19: A Comprehensive In Silico Based Review

被引:3
|
作者
Agrawal, Neetu [1 ]
Pathak, Shilpi [1 ]
Goyal, Ahsas [1 ]
机构
[1] GLA Univ, Pharmaceut Res Inst, Mathura 281406, Uttar Pradesh, India
关键词
COVID-19; SARS-CoV-2; Papain-like protease; PLpro; in silico; molecular docking;
D O I
10.2174/1386207325666211122123602
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The entire world has been in a battle against the COVID-19 pandemic since its first appearance in December 2019. Thus researchers are desperately working to find an effective and safe therapeutic agent for its treatment. The multifunctional coronavirus enzyme papain-like protease (PLpro) is a potential target for drug discovery to combat the ongoing pandemic responsible for cleavage of the polypeptide, deISGylation, and suppression of host immune response. The present review collates the in silico studies performed on various FDA-approved drugs, chemical compounds, and phytochemicals from various drug databases and represents the compounds possessing the potential to inhibit PLpro. Thus this review can provide quick access to a potential candidate to medicinal chemists to perform in vitro and in vivo experiments who are thriving to find the effective agents for the treatment of COVID-19.
引用
收藏
页码:1838 / 1858
页数:21
相关论文
共 50 条
  • [1] Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19
    Hersi, Fatema
    Sebastian, Anusha
    Tarazi, Hamadeh
    Srinivasulu, Vunnam
    Mostafa, Ahmed
    Allayeh, Abdou Kamal
    Zeng, Cong
    Hachim, Ibrahim Y.
    Liu, Shan-Lu
    Abu-Yousef, Imad A.
    Majdalawieh, Amin F.
    Zaher, Dana M.
    Omar, Hany A.
    Al-Tel, Taleb H.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 254
  • [2] Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs
    Kouznetsova, Valentina L.
    Zhang, Aidan
    Tatineni, Mahidhar
    Miller, Mark A.
    Tsigelny, Igor F.
    PEERJ, 2020, 8
  • [3] In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors
    Elseginy, Samia A.
    Anwar, Manal M.
    RSC ADVANCES, 2021, 11 (61) : 38616 - 38631
  • [4] A novel robust inhibitor of papain-like protease (PLpro) as a COVID-19 drug
    Asl, Saeed Soleimani
    Roozbahani, Mohammad Hossein
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (13): : 6863 - 6870
  • [5] Natural Products as Potential Inhibitors for SARS-CoV-2 Papain-Like Protease: An in Silico Study
    Alvarado-Huayhuaz, Jesus
    Jimenez, Fabian
    Cordova-Serrano, Gerson
    Camps, Ihosvany
    Puma-Zamora, Wilmar
    ADVANCES IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, BSB 2020, 2020, 12558 : 265 - 270
  • [6] SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment
    Stasiulewicz, Adam
    Maksymiuk, Alicja W.
    Nguyen, Mai Lan
    Belza, Barbara
    Sulkowska, Joanna I.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [7] A Patent Review on SARS Coronavirus Papain-Like Protease (PLpro) Inhibitors
    Chia, C. S. Brian
    Lim, Siew Pheng
    CHEMMEDCHEM, 2023, 18 (16)
  • [8] Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
    Amin, Sk. Abdul
    Banerjee, Suvankar
    Ghosh, Kalyan
    Gayen, Shovanlal
    Jha, Tarun
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 29
  • [9] In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
    Huynh, Tien
    Cornell, Wendy
    Luan, Binquan
    FRONTIERS IN CHEMISTRY, 2021, 8
  • [10] Protease inhibitors targeting the main protease and papain-like protease of coronaviruses
    Capasso, Clemente
    Nocentini, Alessio
    Supuran, Claudiu T.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2021, 31 (04) : 309 - 324